Dysbiosis is alterations in the microbial composition compared with a healthy microbiota and often features a reduction in gut microbial diversity and a change in microbial taxa. Dysbiosis, especially in the gut, has also been proposed to play a crucial role in the pathogenesis of a wide variety of diseases, including inflammatory bowel disease, colorectal cancer, cardiovascular disease, obesity, diabetes and multiple sclerosis. A body of evidence has shown that intestinal polymeric immunoglobulin A (IgA) antibodies are important to regulate the gut microbiota as well as to exclude pathogenic bacteria or viral infection such as influenza and SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) at mucosal sites. Since the 1970s, trials for oral administration of therapeutic IgA or IgG have been performed mainly to treat infectious enteritis caused by pathogenic Escherichia coli or Clostridium difficile. However, few of them have been successfully developed for clinical application up to now. In addition to the protective function against intestinal pathogens, IgA is well known to modulate the gut commensal microbiota leading to symbiosis. Nevertheless, the development of therapeutic IgA drugs to treat dysbiosis is not progressing. In this review, the advantages of therapeutic IgA antibodies and the problems for their development will be discussed.

中文翻译：

---

用于生态失调相关疾病的治疗性免疫球蛋白 A 抗体。

与健康微生物群相比，生态失调是微生物组成的改变，通常表现为肠道微生物多样性减少和微生物分类群发生变化。生态失调，尤其是在肠道中，也被认为在多种疾病的发病机制中起着至关重要的作用，包括炎症性肠病、结肠直肠癌、心血管疾病、肥胖症、糖尿病和多发性硬化症。大量证据表明，肠道聚合免疫球蛋白 A (IgA) 抗体对于调节肠道微生物群以及排除流感和 SARS-CoV-2（严重急性呼吸系统综合症冠状病毒 2）等病原体或病毒感染很重要。粘膜部位。自 1970 年代以来，口服治疗性 IgA 或 IgG 的试验主要用于治疗由致病性大肠杆菌或艰难梭菌引起的感染性肠炎。然而，迄今为止，它们中很少有人成功开发用于临床应用。除了针对肠道病原体的保护功能外，众所周知，IgA 还可以调节肠道共生微生物群，导致共生。然而，用于治疗生态失调的治疗性 IgA 药物的开发并未取得进展。在这篇综述中，将讨论治疗性 IgA 抗体的优势及其开发中的问题。众所周知，IgA 可调节肠道共生微生物群，导致共生。然而，用于治疗生态失调的治疗性 IgA 药物的开发并未取得进展。在这篇综述中，将讨论治疗性 IgA 抗体的优势及其开发中的问题。众所周知，IgA 可调节肠道共生微生物群，导致共生。然而，用于治疗生态失调的治疗性 IgA 药物的开发并未取得进展。在这篇综述中，将讨论治疗性 IgA 抗体的优势及其开发中的问题。